MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 524943 | Name: Dazmegrel

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Dazmegrel also known as UK 38,485, is a highly effective and selective thromboxane A2 (TXA2) synthetase inhibitor.

Chemical Structure

Dazmegrel
Dazmegrel
CAS#76894-77-4

Theoretical Analysis

MedKoo Cat#: 524943

Name: Dazmegrel

CAS#: 76894-77-4

Chemical Formula: C16H17N3O2

Exact Mass: 283.1321

Molecular Weight: 283.33

Elemental Analysis: C, 67.83; H, 6.05; N, 14.83; O, 11.29

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Dazmegrel; Dazmegrel; UK 38,485; UK-38,485; UK38,485; UK 38485; UK-38485; UK38485.
IUPAC/Chemical Name
3-(Imidazol-1-ylmethyl)-2-methylindole-1-propionic acid
InChi Key
DEQLGSOHGTZKFB-UHFFFAOYSA-N
InChi Code
InChI=1S/C16H17N3O2/c1-12-14(10-18-9-7-17-11-18)13-4-2-3-5-15(13)19(12)8-6-16(20)21/h2-5,7,9,11H,6,8,10H2,1H3,(H,20,21)
SMILES Code
O=C(O)CCN1C(C)=C(CN2C=CN=C2)C3=C1C=CC=C3
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 283.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Kemppainen BW, Urry DW, Luan CX, Xu J, Swaim SF, Goel S. In vitro skin penetration of dazmegrel delivered with a bioelastic matrix. Int J Pharm. 2004 Mar 1;271(1-2):301-3. PubMed PMID: 15129998. 2: D'Souza RJ, Phillips HM, Radeke HH, Aber GM, Strange RC. Mesangial cell DNA synthesis induced by hydrogen peroxide, interleukin-6, and platelet-derived growth factor: effects of indomethacin and dazmegrel. Nephron. 1996;72(2):263-8. PubMed PMID: 8684537. 3: Norris LA, Sheppard BL, Bonnar J. Increased whole blood platelet aggregation in normal pregnancy can be prevented in vitro by aspirin and dazmegrel (UK38485). Br J Obstet Gynaecol. 1992 Mar;99(3):253-7. PubMed PMID: 1606123. 4: Salinas P, Barrigón S. Protective effects of dazmegrel on the PAF potential of ouabain-induced cardiac arrhythmias. Eur J Pharmacol. 1991 Dec 10;209(1-2):105-7. PubMed PMID: 1814756. 5: Gladue RP, Newborg MF. The protective effects of the thromboxane synthetase inhibitor Dazmegrel on nephrotoxicity in cyclosporine-treated rats. Transplantation. 1991 Nov;52(5):837-41. PubMed PMID: 1949170. 6: Truog WE, Gibson RL Jr, Henderson WR, Redding GJ. Tumor necrosis factor-induced neonatal pulmonary hypertension: effects of dazmegrel pretreatment. Pediatr Res. 1990 May;27(5):466-71. PubMed PMID: 2345673. 7: Pärsson H, Jönsson BA, Norgren L, Thörne J. The effect of dextran 40 and Dazmegrel on early platelet deposition onto vascular grafts. Vasa. 1990;19(3):242-6. PubMed PMID: 1700560. 8: Rebec MV, Skrinska VA. Pharmacology of UK-38485 (dazmegrel), a specific inhibitor of thromboxane A2 synthetase. Prostaglandins Leukot Essent Fatty Acids. 1989 Dec;38(3):207-12. PubMed PMID: 2622975. 9: Wang SL. [Effect of the thromboxane synthetase inhibitor dazmegrel (UK 38,485) on skin blood flow in deep partial thickness burns]. Zhonghua Zheng Xing Shao Shang Wai Ke Za Zhi. 1989 Sep;5(3):206-9, 239-40. Chinese. PubMed PMID: 2514031. 10: Archer RL, Cunningham AC, Moore PF, Potter JA, Bliven ML, Otterness IG. Effects of dazmegrel, piroxicam and cyclophosphamide on the NZB/W model of SLE. Agents Actions. 1989 Jun;27(3-4):369-74. PubMed PMID: 2801326. 11: Rebec MV, Skrinska VA. High-performance liquid chromatography with fluorescence detection of dazmegrel, a specific thromboxane A2 synthetase inhibitor. J Chromatogr. 1988 Nov 18;432:375-80. PubMed PMID: 3220909. 12: Truog WE, Gibson RL, Juul SE, Henderson WR, Redding GJ. Neonatal group B streptococcal sepsis: effects of late treatment with dazmegrel. Pediatr Res. 1988 Apr;23(4):352-6. PubMed PMID: 3287320. 13: Belch JJ, Saniabadi AR, McLaughlin K, Forbes CD. Platelet changes after a saturated fat meal and their prevention by Dazmegrel, a thromboxane synthetase inhibitor. Lipids. 1987 Mar;22(3):159-62. PubMed PMID: 3573995. 14: Kay S, Green C. The effect of a novel thromboxane synthetase inhibitor dazmegrel (UK38485) on random pattern skin flaps in the rat. Br J Plast Surg. 1986 Jul;39(3):361-3. PubMed PMID: 3730684. 15: Wang SL, Silberstein EB, Lukes S, Robb E, Zou WZ, Bruno L, Heyd TJ, Waymack JP, Alexander JW. The effect of the thromboxane synthetase inhibitor Dazmegrel (UK-38,485) on wound healing, dermal ink perfusion and skin blood flow measurements in deep partial thickness burns. Burns Incl Therm Inj. 1986 Jun;12(5):312-7. PubMed PMID: 3730910. 16: Wang SL, Waymack JP, Alexander JW. Effect of Dazmegrel (UK-38,485) on immune function in a burned guinea-pig model. Burns Incl Therm Inj. 1986 Jun;12(5):307-11. PubMed PMID: 3730909. 17: Truog WE, Sorensen GK, Standaert TA, Redding GJ. Effects of the thromboxane synthetase inhibitor, dazmegrel (UK 38,485), on pulmonary gas exchange and hemodynamics in neonatal sepsis. Pediatr Res. 1986 May;20(5):481-6. PubMed PMID: 3520468. 18: Langleben D, Carvalho AC, Reid LM. The platelet thromboxane inhibitor, dazmegrel, does not reduce monocrotaline-induced pulmonary hypertension. Am Rev Respir Dis. 1986 May;133(5):789-91. PubMed PMID: 3085563. 19: Lorenz RL, Fischer S, Wober W, Wagner HA, Weber PC. Effects on prostanoid formation and pharmacokinetics of dazmegrel (UK-38,485), a novel thromboxane synthase inhibitor, in man. Biochem Pharmacol. 1986 Mar 1;35(5):761-6. PubMed PMID: 3513767. 20: Bullock GR, Leprán I, Parratt JR, Szekeres L, Wainwright CL. Effects of a combination of metoprolol and dazmegrel on myocardial infarct size in rats. Br J Pharmacol. 1985 Sep;86(1):235-40. PubMed PMID: 4052726; PubMed Central PMCID: PMC1916875.